Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

Anticipation. Prurisol "SUCCESSFUL" and compassionate use coming.



Soon.



Kevetrin continues to be successful. Looking forward to their next steps.

Brilacidin heading for partnership to move forward.

Excellent track record. The desperation is looking pretty clear to get this as cheap as they can before the market realizes what they're missing out on. A major gap up on partnership news would do it. Good to great prurisol news may do it as well. At that moment, charts are meaningless.

All imho.

Message in reply to:

IPIX Clinical Trial Timelines

2012
1. Kevetrin (Phase 1)

2013
1. Kevetrin (Phase 1)

2014
1. Kevetrin (Phase 1)
2. Brilacidin-ABSSSI (Phase 2b)
3. Prurisol (Phase 1)

2015
1. Kevetrin (Phase 1)
2. Brilacidin-ABSSSI (Phase 2b, Successful)
3. Brilacidin-OM (Phase 2)
4. Prurisol (Phase 1, Successful)
5. Prurisol (Phase 2a)

2016
1. Kevetrin (Phase 1, Successful)
2. Brilacidin-ABSSSI (Phase 2b, Successful)
3. Brilacidin-OM (Phase 2)
4. Brilacidin-UP (Phase 2 POC)
5. Prurisol (Phase 1, Successful)
6. Prurisol (Phase 2a, Successful)
7. Prurisol (Phase 2b)

2017
1. Kevetrin (Phase 1, Successful)
2. Kevetrin-OC (Phase 2a, Successful)
3. Brilacidin-ABSSSI (Phase 2b, Successful)
4. Brilacidin-OM (Phase 2, Successful)
5. Brilacidin-UP (Phase 2 POC, Successful)
6. Prurisol (Phase 1, Successful)
7. Prurisol (Phase 2a, Successful)
8. Prurisol (Phase 2b)

https://clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search

Message in reply to:

BP's interests in the Big Three

“The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review."

http://www.ipharminc.com/press-release/2018/1/29/innovation-pharmaceuticals-brilacidin-franchise-anchored-in-three-clinical-indications-oral-mucositis-inflammatory-bowel-disease-and-serious-skin-infections-expands-into-dermatologic-diseases

“These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,”

http://www.ipharminc.com/press-release/2018/1/16/innovation-pharmaceuticals-presents-at-2018-biotech-conference-oral-mucositis-drug-candidate-garners-exceptional-interest-after-successful-phase-2-trial

"To advance our pipeline in an expeditious manner, this year we placed an emphasis on partnering—actively engaging global and regional pharmaceutical companies interested in licensing our novel drug candidates. These efforts have led to highly productive, mature (late-phase, ongoing) discussions, with multiple pharmaceutical companies, which we hope will bear fruit in the coming year." - CEO Letter to Shareholders

"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."

https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript

B-Dermatitis

"To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets."

http://www.ipharminc.com/press-release/2018/1/29/innovation-pharmaceuticals-brilacidin-franchise-anchored-in-three-clinical-indications-oral-mucositis-inflammatory-bowel-disease-and-serious-skin-infections-expands-into-dermatologic-diseases

B-OM

“Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.”

http://www.ipharminc.com/press-release/2017/11/16/innovation-pharmaceuticals-offers-perspectives-on-brilacidin-as-a-potential-preventative-treatment-for-oral-mucositis-in-head-and-neck-cancer-patients

B-UP

"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."

https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript

Prurisol

"We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship."

https://www.sec.gov/Archives/edgar/data/1355250/000147793217004400/ipix_10k.htm

Kevetrin

"The Company is adhering to a value-building strategy born from discussions with larger pharmaceutical companies interested in Kevetrin, one of the world’s most advanced p53 drug candidates. Securing the right development partner for Kevetrin remains an important objective."

http://www.ipharminc.com/press-release/2018/2/8/innovation-pharmaceuticals-concludes-successful-phase-2a-trial-of-kevetrin-for-ovarian-cancer-intra-tumor-modulation-of-p53-observed

"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,"

http://www.ipharminc.com/press-release/2017/9/14/innovation-pharmaceuticals-opens-new-clinical-site-for-novel-p53-drug-candidate-in-phase-2-ovarian-cancer-trial-1

Excellent post by Detonate as well...

Message in reply to:

Of course a trial could not take place without "Somebody always knows something" but you're saying "somebody" has shared what they know the chart reflects this. And this "always" happens.

You also stated, "If there was 'good news' coming in the future IPIX would rally, but it is not so the most likely the news is bad news ,that is what the chart is telling us."

I think your chart is more a reflection of your efforts than it is on some dishonest person sharing what they know about trial results.

The market's history has thousands if not tens of thousands of examples where an after hours announcement has led to the following open at multiple times the previous close. Shorts get fried and those sitting on the fence lament not having bought shares. How does this happen? It happens because the market didn't "know" in advance.

The all knowing charts failed them.

It can get very interesting here, very quickly.

$IPIX